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1  |  INTRODUC TION
Parasite diseases cause productivity losses in dairy animals, with 
economic effects that can be reduced using anthelmintic therapy 
(Vercruysse & Claerebout, 2001). Despite their benefits, anthelmint-
ics used in dairy cows cause public health and food safety concerns 
due to the unwanted presence of drug residues in milk (Imperiale 
et al., 2004; Tsiboukis et al., 2013). Macrocyclic lactones (MLs) 
are anthelmintic drugs with endo- and ectoparasiticidal activity 
(Campbell, 1983; Vercruysse & Rew, 2002). Overall, MLs are con-
sidered to have similar biological activity; however, differences in 
the chemical structure among MLs members account for specific 
pharmacokinetic (PK) and pharmacodynamic (PD) features (Lanusse, 
1997). In addition, the ML structure also has a significant effect on 
the distribution rate between milk and plasma and, consequently, on 
the presence of drug residues in milk (McKellar & Gokbulut, 2012). 
This topic is an important factor influencing the selection of treat-
ments to be applied in dairy animals, considering the importance 
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Abstract
This study aimed at determining the plasma disposition kinetics of eprinomectin 
(EPM) and EPM excretion pattern through milk after topical administration to dairy 
cattle at the recommended dose of 0.5 mg/kg and at 1 and 1.5 mg/kg. A high vari-
ability in the plasma concentration profiles was observed among animals, particularly 
in the Cmax values, with a coefficient of variation between 39 and 53%. The Cmax 
and AUC values were significantly affected by the dose administered at 1.5 mg/kg. 
However, such differences did not seem to follow a linear pattern among treatments. 
These parameters did not differ among dose rates after dose normalization; neverthe-
less, the simulation of a linear kinetic disposition showed a mean plasma AUC value of 
254 ng.d/ml instead of the observed value of 165 ng.d/ml. EPM concentration profiles 
in milk were significantly lower than those measured in plasma. The Cmax and AUC 
milk- to- plasma ratios ranged from 0.14 to 0.26 and 0.16 to 0.21, respectively (p>0.05). 
The low milk- to- plasma ratio of EPM accounted for a low percentage of the fraction 
of the administered dose excreted through milk, being significantly higher at a dose 
rate of 0.5 mg/kg (0.07%) of EPM than at 1.5 mg/kg (0.04%) (p<0.05). The topical 
administration of EPM to lactating dairy cows at higher doses than that recommended 
for gastrointestinal nematodes showed a milk excretion pattern with a zero milk with-
drawal period. In conclusion, the administration of topical EPM formulation at 1 or 
1.5 mg/kg may be a valuable tool to be used in regional strategic deworming programs 
aimed to control ectoparasite infections in dairy production systems.
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of reducing the withdrawal times of anthelmintic treatments (Nava 
et al., 2015).
Eprinomectin (EPM), an ML member, is an amino- avermectin 
derivative of avermectin B1 analogues. EPM shows a similar broad- 
spectrum activity against nematodes and arthropods to that of 
the other MLs (Shoop et al., 2001; Williams et al., 1999). However, 
changes in the chemical structure of EPM determine a lower milk 
partitioning coefficient than that of other ML members (Shoop et al., 
1996). The pioneer EPM formulation at 0.5% was topically adminis-
tered to dairy cows and has the advantage of zero- day withdrawal in 
milk. For this reason, in Argentina, it is used for controlling ectopar-
asites, such as Riphichephalus (Boophilus) microplus (R. (B.) microplus), 
which affect dairy cows in endemic areas. The administration regime 
of EPM is based on previous works that investigated the acaricidal 
activity and PK of EPM following different administration protocols 
for beef cattle. The efficacy of EPM against R. (B.) microplus was 
evaluated in a double application treatment regimen with a 4- day 
interval between treatments at 0.5 mg/kg (Davey & George, 2002) 
and in a single administration at 1 mg/kg (Aguirre et al., 2005). An 
integrated study on the PK and efficacy of EPM topically adminis-
tered at doses 2 and 3 times (1 and 1.5 mg/kg) higher than the ther-
apeutic dose was conducted (Lifschitz et al., 2016). However, there 
is no available information about the influence of EPM dose rate on 
the systemic exposure and drug residues in milk after the topical ad-
ministration to dairy cattle. The present study evaluated the plasma 
disposition kinetics and the excretion pattern of EPM through milk 
after topical administration to dairy cattle at the recommended dose 
of 0.5 mg/kg and at 1 and 1.5 mg/kg.
2  |  MATERIAL S AND METHODS
2.1  |  Experimental animals, treatment and 
sampling
Eighteen clinically healthy Holando Argentino cows in the late 
stage of lactation were used; their mean body weight was 622 ± 
68 kg. The study was conducted in the dairy farm of the School of 
Agrarian Education N° 1 ‘Dr. Ramón Santamarina’, located in Tandil, 
Argentina. Cows were milked twice a day using mechanical vacuum 
milking machines, and milk production was measured before the 
start of and throughout the trial. The average milk production during 
the experimental period was 23.5 ± 3.10 l/animal/day. The animal 
health status was monitored throughout the study. Dosages were 
calculated based on individual body weight, and the treatment was 
started after milking process was completed. Experimental animals 
were allocated to three experimental groups of six animals each and 
treated with a commercial formulation of eprinomectin (EPM) 0.5% 
solution (IVOMEC® EPRINEX® POUR ON, Merial Argentina S.A.) at 
0.5 mg/kg (EPM 0.5mg/kg), 1 mg/kg (EPM 1mg/kg) and 1.5 mg/kg 
(EPM 1.5mg/kg). EPM solution was applied topically (pour- on) on 
day 0 directly on the skin along the back line from the withers to the 
tail head. The animal health status was monitored throughout the 
study. No adverse reactions were observed at the site of applica-
tion after treatment. Blood samples were taken from the jugular vein 
into heparinized vacutainer tubes (Becton Dickinson, Franklin Lakes, 
NJ) before and at 1, 2, 3, 5, 7, 9, 11, 15 and 21 days post- treatment. 
Plasma was separated by centrifugation at 2000 g for 20 min, and 
the recovered plasma was transferred into labelled vials. Milk sam-
ples were collected following the same plasma scheme. At each sam-
pling time, a composite milk sample (50 ml, from the four udders) was 
collected by hand milking after discarding 30– 50 ml and before the 
complete mechanical milking of each cow. Plasma and milk samples 
were stored at −20℃ until processing.
3  |  ANALY TIC AL PROCEDURES
3.1  |  Reagents
Pure reference standards of EPM and abamectin (ABM) were used 
to validate the high- performance liquid chromatography (HPLC) 
method. Standard solutions of EPM were prepared by successive 
dilutions in methanol from the parent stock solution (1 mg/ml) and 
stored at - 18° C. A concentration of 10 ng of ABM, used as internal 
standard (IS), was added to both fortified and experimental sam-
ples. Acetonitrile and methanol solvents used during extraction and 
chromatographic analysis were HPLC grade and purchased from 
JT Baker® (Center Valley, PA, US). Water was double distilled and 
deionized using a water purification system (Simplicity®, Millipore, 
Sao Paulo, Brazil).
3.2  |  Drug extraction, derivatization and 
chromatographic conditions
EPM and ABM were extracted from spiked and experimental 
samples (plasma and milk) following the methodology described 
by Imperiale et al. (2006). Briefly, a 0.25 ml- aliquot of plasma and 
1 ml- aliquot of milk was combined with 10 ng of IS (ABM) mixed 
with 1 ml of acetonitrile. The solvent sample was mixed for 20 min 
and then centrifuged at 2000 g for 15 min. The supernatant was 
injected into a C18 cartridge (Strata®, Phenomenex, CA, US), 
previously conditioned by passing 2 ml of methanol and 2 ml of 
deionized water. The cartridge was flushed with 1 ml of water fol-
lowed by 1 ml of water/methanol (4:1, v/v). The compounds were 
eluted with 1.5 ml of methanol and concentrated to dryness under 
a nitrogen stream. Samples were subjected to derivatization, as 
described by Danaher et al. (2001). Once the reaction was com-
pleted, an aliquot (100 µl) of each sample was injected directly 
into the chromatographic system. Concentrations of EPM were 
determined using a Shimadzu LC- 10ATVP HPLC system (Shimadzu 
Corporation, Kyoto, Japan), which included a fluorescence detector 
set at an excitation wavelength of 365 nm and an emission wave-
length of 475 nm. The mobile phase of deionized water, methanol, 
triethylamine, phosphoric acid and acetonitrile (6:25:0.2:0.2:68.6, 
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v/v/v/v/v) was pumped at a flow rate of 1.0 ml/min through a 
C18 reverse- phase column (5 m, 250 by 4.60 mm; Kromasil, Eka 
Chemicals, Bohus, Sweden) kept in an oven set at 30℃. EPM was 
identified by matching their retention times with those of pure ref-
erence standards. Chromatographic peak areas were determined 
using the integrator software (Class LC 10 Software, version 1.2, 
Shimadzu Corporation) of the HPLC system.
3.3  |  Validation method
A complete validation of the analytical procedures for extraction 
and quantification of EPM from both plasma and milk was performed 
before analysing the experimental samples. Calibration curves were 
constructed in the range between 0.1 to 100 ng/ml (plasma) and 0.1 
to 10 ng/ml (milk) and were established using least squares linear 
regression analysis. Correlation coefficients (r) and coefficient of 
variations (CV) were calculated. Linearity was established to de-
termine the EPM concentrations/detector responses relationship. 
Percentages of EPM recovery from plasma and milk were >70%. 
The precision of the extraction and chromatography procedures for 
plasma and milk samples was estimated by processing replicate ali-
quots (n= 4) of samples containing known EPM concentrations. The 
precision showed a coefficient of variation <5% for both matrices. 
The limit of quantification was established at 0.1 ng/ml for both set 
of samples.
3.4  |  Pharmacokinetics and statistical 
analysis of the data
The plasma and milk concentration vs. time curves obtained 
after treatment of each individual animal were fitted with the PK 
Solutions 2.0 (Ashland, OH, US) computer software. PK parameters 
were determined by the non- compartmental analysis. The peak 
plasma concentration (Cmax) was obtained from the plotted plasma 
concentration- time curve of each individual animal. The area under 
the concentration- versus- time curves (AUC) was calculated by the 
trapezoidal rule (Gibaldi & Perrier, 1982) and further extrapolated 
to infinity. The terminal (elimination) half- life (T1/2el) was calculated 
as In2/λz, where In2 is the natural logarithm of 2 and λz, the slope of 
the terminal phase. The λz was determined by performing regres-
sion analysis using at least four points of the terminal phase of the 
concentration- time plot. The percentage of drug elimination through 
milk was calculated using the following equation:
where Vmilk is the individual milk production (ml); Cmilk is the drug con-
centration in milk (ng/ml), and D is the total administered dose (mg).
The plasma exposure after EPM administration at 1 and 
1.5 mg/kg was simulated based on the calculation of a linear kinetic 
disposition of both doses after the administration at 0.5 mg/kg using 
PCModfit 6.9 software (Allen, 1990). The estimated values were 
compared to those observed after EPM quantification in plasma for 
each dose rate.
Plasma and milk concentrations of EPM and all the PK parame-
ters are reported as mean ±SD. Mean PK parameters were statis-
tically compared using one- way ANOVA. The assumption of equal 
variance of the data obtained after treatments was assessed using 
a non- parametric Kruskal– Wallis test, which showed significant dif-
ferences among standard deviations. A similar procedure was used 
to compare drug concentrations measured in plasma and milk. The 
statistical analysis was performed using Instat 3.0 Software (Graph 
Pad Software, CA, US). A value of p<0.05 was considered statisti-
cally significant.
4  |  RESULTS
EPM plasma concentrations in dairy cows were measured from day 1 
of topical administration at 0.5, 1 and 1.5 mg/kg, and during the whole 
sampling period up to 21 days. The plasma concentrations vs. time 
profiles of EPM obtained for each treatment are plotted in Figure 1. 
Disposition kinetics of EPM was characterized by a slow absorption 
up to maximal concentrations reached between 2.17 and 3 days post- 
administration, followed by a progressive decrease of drug concen-
trations until comparable levels among groups were reached, about 
9 days post- treatment. There were not significant differences among 
Tmax values in plasma after the administration of the different doses. 
EPM was detected in plasma until day 21. A high variability in the 
plasma concentrations profiles was observed among animals, particu-
larly in Cmax, which had a coefficient of variation between 39 and 
53%. A summary of the main plasma PK parameters for the differ-
ent dose regimens is presented in Table 1. The Cmax and AUC values 
were significantly affected by the dose administered only for 1.5 mg/
kg. However, such differences did not seem to follow a linear pattern 
among treatments. After dose normalization, these parameters did 
% doseexcreted throughmilk = (Vmilk × Cmilk∕D) × 100.
F I G U R E  1  Comparative (mean ±SD, n=6 per group) plasma 
concentration profiles (ng/ml) of eprinomectin (EPM) obtained 
after topical (pour- on) administration to dairy cows at 0.5, 1 and 
1.5 mg/kg. The insert shows the mean simulated concentrations 
obtained after the 0.5 and 1.5 mg/kg doses based on a linear 
kinetic disposition calculation
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not differ among the different dose rates; nevertheless, the simula-
tion of a linear kinetic disposition showed a mean plasma AUC value 
of 254 ng.d/ml instead of the observed value of 165 ng.d/ml.
In all experimental animals, EPM was detected in milk until day 
15 post- administration. The milk concentration profiles of EPM 
after topical administration at different dose rates are shown in 
Figure 2. Milk concentrations of EPM were significantly lower than 
those measured in plasma. Tmax in milk was significantly delayed 
after the administration of 1 mg/kg compared to the other two 
doses. Table 2 shows the comparative PK parameters for EPM in 
milk for each experimental group. The Cmax and AUC milk- to- 
plasma ratios ranged from 0.14 to 0.26 and 0.16 to 0.21, respec-
tively, without differences among experimental groups (Figure 3). 
There was a significant correlation between Tmax values in plasma 
and those achieved in milk (r 0.52, p 0.02). The low milk- to- plasma 
ratio of EPM accounted for a low percentage of the fraction of 
administered dose excreted in milk. This fraction was signifi-
cantly higher when EPM was administered at 0.5 mg/kg (0.07%) 
than at 1.5 mg /kg (0.04%) (p<0.05). EPM concentrations in milk 
were below the maximum residue limit (20 ng/mL) throughout the 
whole sampling period after its administration at the three dose 
rates tested.
5  |  DISCUSSION
Successful management of anthelmintic drugs requires integration 
of pharmacological, parasitological and epidemiological knowledge. 
Topical administration of ML shows advantages and disadvantages 
in the different cattle production systems. These commercial for-
mulations should be easy to deliver and reduce stressful condi-
tions of animals. However, physio- pharmacological factors, such as 
breed, body composition and licking behaviour, may trigger a highly 
variable pharmacokinetic and pharmacodynamic response (Laffont 
et al., 2001; Sallovitz et al., 2002; Toutain et al., 2012). The high 
variability in the efficacy against gastrointestinal nematodes after 
topical administration of ML was clearly corroborated by Leathwick 
and Miller (2013). In the current trial, the variability in the Cmax and 
Tmax of EPM in plasma was between 36 and 74% after administra-
tion at the three dose rates. Whereas the EPM Tmax values were 
similar in plasma after the administration of the three doses, a sig-
nificant delayed Tmax was measured in milk after the administration 
of 1 mg/kg (Table 2). It seems that this result does not have a physio- 
pharmacological relevance. EPM milk concentrations remained at 
very low and constant levels during the first days after treatment 
and small variations may determine that the Cmax was achieved on 
day 2, 3 or 5.
Since injectable MLs are not approved for use in lactating dairy 
cows, EPM is considered a first- line treatment option because it has 
a zero- day milk withdrawal period. The impact of gastrointestinal 
parasitism on adult dairy cows has been studied over many years. 
Since the distribution of gastrointestinal nematodes in adult dairy 
cows is over- dispersed, the negative impact on milk production may 
be variable and a targeted selective treatment is recommended 








Tmax (days) 2.67 ± 1.86a 3.00 ± 1.10a 2.17 ± 1.60a 0.637
Cmax (ng/ml) 14.1 ± 7.49a 24.6 ± 9.59ab 30.7 ± 13.9b 0.047
AUC0- 21d (ng.d/ml) 80.0 ± 15.3
a 136 ± 50.9ab 165 ± 44.7b 0.007
T1/2el (days) 3.34 ± 1.08
a 2.47 ± 0.47a 2.67 ± 0.49a 0.134
MRT (days) 5.93 ± 1.37a 4.62 ± 0.38a 4.77 ± 0.68a 0.072
*Normalized Cmax 14.1 ± 7.49a 12.3 ± 4.79a 10.2 ± 4.62a 0.534
*Normalized AUC 80.0 ± 15.3a 67.8 ± 25.4a 54.8 ± 14.9a 0.108
Note: Different letters indicate statistical differences at p<0.05.
Abbreviations: AUC0- 21d, area under the concentration vs. time curve from time zero to 21 days 
post- administration; Cmax, peak plasma concentration; MRT, mean residence time; T½el, 
elimination half- life; Tmax, time to peak plasma concentration.
*Cmax and AUC values were dose- normalized by dividing the obtained values by 2 (EPM 1mg/kg) 
and 3 (EPM 1.5mg/kg).
TA B L E  1  Pharmacokinetic parameters 
(mean ±SD, n=6 per group) for 
eprinomectin (EPM) in plasma after topical 
administration to dairy cows at 0.5, 1 and 
1.5 mg/kg
F I G U R E  2  Comparative (mean ±SD, n=6 per group) milk 
concentration profiles (ng/ml) of eprinomectin (EPM) obtained 
after topical (pour- on) administration to dairy cows at 0.5, 1 and 
1.5 mg/kg
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located in endemic areas, where tick (Rhipicephalus (Boophilus) mi-
croplus) infestation was found to reduce milk yield and liveweight 
gain during lactation (Jonsson et al., 1998). In Argentina, EPM is com-
mercially registered as a 0.5% w/v pour- on formulation and may be 
an attractive therapeutical option for controlling ticks. The topical 
administration of EPM to dairy cows is especially advantageous be-
cause drug residues in milk after the recommended dose of 0.5 mg/
kg are below the maximum level of residues of 20 ng/ml (Alvinerie 
et al., 1999).
Different treatment strategies against ticks were evaluated for 
EPM. After single and double applications of EPM at the dose rec-
ommended for the control of internal parasites (0.5 mg/kg), a high 
efficacy against ticks was observed in calves (Daves & George, 
2002). In fact, those authors recommended doses two to three 
times higher to obtain higher tick control. This strategy was tested 
later by applying the topical EPM formulation to calves infected with 
ticks at 1 and 1.5 mg/kg (Aguirre et al., 2005; Lifschitz et al., 2016). 
In those trials, a high efficacy against ticks was obtained after EPM 
administration at both dose rates, without significant differences 
in the number of ticks between the administered doses, but with 
the 1.5 mg/kg having a higher effect on reproductive parameters 
(Lifschitz et al., 2016). The previous estimation of EPM disposition 
in milk using plasma concentrations in calves treated with EPM at 1 
and 1.5 mg/kg concluded that the drug levels would be below 20 ng/
ml (Lifschitz et al., 2016). However, to establish the effective and 
safe drug dosage regimens for EPM at higher dose rates in lactating 
dairy cows, plasma disposition kinetics and milk excretion pattern 
should be characterized to ensure that drug levels in milk are below 
the maximum residue limit. Our results corroborated milk EPM con-
centrations in dairy cows, with EPM milk Cmax ranging between 
1.86 (0.5 mg/kg) and 5.86 ng/mL (1.5 mg/kg); this is a safe level, 
taking into account the maximum level allowed. This issue is very 
important due to the widespread use of long- acting formulation of 
MLs for controlling ticks in South America. The long- acting formu-
lation provides sustained concentrations based on a slow release 
from the subcutaneous injection site (Lifschitz et al., 2007) and may 
prevent tick re- infestations (Nava et al., 2015). However, successive 
treatments with long- acting ivermectin (IVM) formulations increase 
its accumulation in cattle tissues (Nava et al., 2019), which may ex-
tend the withdrawal period indicated for the commercial product. 
Moreover, these formulations are not permitted for use in lactating 
dairy cows, which require the administration of products with a zero 
or very short milk withdrawal period. Thus, although the pharmaco-
kinetics of EPM has been extensively studied in cattle at a dose of 
0.5 mg/kg, the present study evaluated for the first time the com-
parative milk- to- plasma distribution pattern of EPM administered 
at 0.5, 1 and 1.5 mg/kg in dairy cows. The main results confirmed 
that the expected low concentrations of EPM excreted in milk were 
below the maximum residue levels, even at 2 and 3 times the ap-
proved dose.
The comparison of the plasma- milk disposition of EPM after 
administration of different dose rates of EPM to dairy cows 
showed interesting results. The mean plasma availability of EPM 
obtained in this study in dairy cows was 1.6- (136 vs. 213 ng/
ml at 1 mg/kg) and 2.3- (165 vs. 382 ng/ml at 1.5 mg/kg) fold 
lower than that reported for beef cattle (Lifschitz et al., 2016). 
Such variability may reflect differences in animal physiology and 
body condition between beef cattle and lactating dairy cows. In 








Tmax (days) 2.50 ± 1.22a 4.67 ± 0.82b 2.83 ± 1.33a 0.010
Cmax (ng/ml) 3.67 ± 1.57a 3.77 ± 0.94a 4.32 ± 1.15a 0.629
AUC0- 15d (ng.d/ml) 16.2 ± 3.42
a 21.6 ± 6.72ab 27.7 ± 7.27b 0.017
T1/2el (days) 2.43 ± 0.10
a 2.21 ± 0.22a 2.15 ± 0.29a 0.095
Milk- to- plasma ratioAUC 0.21 ± 0.04
a 0.16 ± 0.03a 0.17 ± 0.03a 0.059
Dose excreted through milk (%) 0.07 ± 0.03a 0.05 ± 0.01ab 0.04 ± 0.01b 0.043
Note: Different letters indicate statistical differences at p<0.05.
Abbreviations: AUC0- 15d, area under the concentration vs. time curve from time zero to 15 days 
post- administration; Cmax, peak plasma concentration; MRT, mean residence time; T½el, 
elimination half- life; Tmax, time to peak plasma concentration.
TA B L E  2  Representative 
pharmacokinetic parameters (mean ±SD, 
n=6 per group) for eprinomectin (EPM) in 
milk after topical administration to dairy 
cows at 0.5, 1 and 1.5 mg/kg
F I G U R E  3  Milk- to- plasma ratios (mean ±SD, n=6 per group) of 
peak concentrations (Cmax) and area under the concentration vs. 
time curves (AUC) calculated after topical (pour- on) administration of 
eprinomectin (EPM) to dairy cows at a dose of 0.5, 1 and 1.5 mg/kg
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observed in lactating and non- lactating goats corroborating that 
the physiological status affects the disposition of lipophilic mole-
cules (Dupuy et al., 2001).
Dose- normalized systemic availability did not show significant dif-
ferences between groups treated with twofold and threefold higher 
doses than the recommended one. However, a simulation was done 
based on the observed data obtained after administration at 0.5 mg/kg, 
to simulate the behaviour of the other doses following a linear pharma-
cokinetics. The simulation resulted in a systemic availability 1.54- fold 
higher than that observed after administration at 1.5 mg/kg. Although 
a constant ratio of the milk- to- plasma concentrations was observed 
after the administration of the three dose rates, the percentage of dose 
excreted in milk was significantly lower after the administration of 
EPM at 1.5 mg/kg compared to that obtained after its administration 
at 0.5 mg/kg. The occurrence of a skin depot effect after the pour- on 
administration of MLs ivermectin and moxidectin to cattle was previ-
ously reported (Laffont et al., 2003; Sallovitz et al., 2003). The abso-
lute bioavailability of ivermectin administered topically to cattle was 
23% with 77% of the dose remaining on the skin (Laffont et al., 2003). 
After the topical administration of moxidectin, the AUC ratio between 
skin and abomasal mucosa was 4.55 for topical treatment vs. 1.02 for 
subcutaneous administration that also reflects the skin depot. In our 
work, a similar effect of skin depot may be occurring with increasing 
doses of EPM. The normalization of the AUC did not show significant 
differences between the administered doses due to the high variabil-
ity and the small number of experimental animals necessary to detect 
these differences. However, the potential skin depot affected the dose 
linearity reducing the mean observed Cmax and AUC values after the 
administration of EPM at 1.5 mg/kg. On the other hand, there was not 
modification in the plasma Tmax, which could be indicating a great ca-
pacity of the skin to retain the drug without observing a significant 
extension in the absorption time.
From the efficacy point of view, the accumulation of EPM in the 
skin of treated animals may be an advantageous tool for controlling 
tick infestation. When EPM is topically administered, its uptake by 
ticks occurs as a combination of feeding habits and the contact with 
the drug depot on the skin surface. In fact, Lifschitz et al. (2016) ob-
served that EPM accumulation in collected ticks from treated calves 
was directly related to the dose rate received. The high EPM concen-
trations measured in ticks during the first two days post- administration 
could be explained by the direct parasite- drug interaction in the skin 
(Lifschitz et al., 2016).
Besides the traditional topical preparation, injectable formula-
tions of EPM were launched to the pharmaceutical market in different 
countries such as South Africa, Turkey and Brazil (Aksit et al., 2016; 
do Nascimento et al., 2020) to be administered subcutaneously at 
0.2 mg/kg. The injectable EPM provides a greater systemic availability 
and peak concentration than the topical administration at 0.5 mg/kg 
but some of them have lost the advantage of the withdrawal period 0 
in milk after their administration in lactating dairy cows. Therefore, the 
administration route, pharmaceutical formulation and dose of EPM 
should be chosen according to the type of parasites to be treated and 
the production system where this drug is going to be used.
6  |  CONCLUSION
The topical administration of EPM to lactating dairy cows at higher 
doses than those recommended for the control of gastrointestinal 
nematodes showed a milk excretion pattern that allows avoidance 
of the withdrawal period in milk. As this therapeutic scheme was 
successfully evaluated in tick infestation, the administration of the 
topical formulation of EPM at 1 or 1.5 mg/kg may be a valuable tool 
to be used in strategic control programs in dairy production systems.
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